Literature DB >> 32684855

Baseline Karnofsky performance status is independently predictive of death within 30 days of intracranial radiation therapy completion for metastatic disease.

Shearwood McClelland Iii1, Namita Agrawal1, May F Elbanna1, Kevin Shiue1, Gregory K Bartlett1, Tim Lautenschlaeger1, Richard C Zellars1, Gordon A Watson1, Susannah G Ellsworth1.   

Abstract

INTRODUCTION: For patients with brain metastases, palliative radiation therapy (RT) has long been a standard of care for improving quality of life and optimizing intracranial disease control. The duration of time between completion of palliative RT and patient death has rarely been evaluated.
METHODS: A compilation of two prospective institutional databases encompassing April 2015 through December 2018 was used to identify patients who received palliative intracranial radiation therapy. A multivariate logistic regression model characterized patients adjusting for age, sex, admission status (inpatient versus outpatient), Karnofsky Performance Status (KPS), and radiation therapy indication.
RESULTS: 136 consecutive patients received intracranial palliative radiation therapy. Patients with baseline KPS <70 (OR = 2.2; 95%CI = 1.6-3.1; p < 0.0001) were significantly more likely to die within 30 days of treatment. Intracranial palliative radiation therapy was most commonly delivered to provide local control (66% of patients) or alleviate neurologic symptoms (32% of patients), and was most commonly delivered via whole brain radiation therapy in 10 fractions to 30 Gy (38% of patients). Of the 42 patients who died within 30 days of RT, 31 (74%) received at least 10 fractions.
CONCLUSIONS: Our findings indicate that baseline KPS <70 is independently predictive of death within 30 days of palliative intracranial RT, and that a large majority of patients who died within 30 days received at least 10 fractions. These results indicate that for poor performance status patients requiring palliative intracranial radiation, hypofractionated RT courses should be strongly considered.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  30-day mortality; Fractionation; Metastatic brain disease; Palliative Care; Performance status; Radiation therapy

Year:  2020        PMID: 32684855      PMCID: PMC7352032          DOI: 10.1016/j.rpor.2020.02.014

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  8 in total

1.  Roentgen-ray therapy of cerebral metastases.

Authors:  J H CHAO; R PHILLIPS; J J NICKSON
Journal:  Cancer       Date:  1954-07       Impact factor: 6.860

2.  Nearly Half of Metastatic Brain Disease Patients Prescribed 10 Fractions of Whole-Brain Radiation Therapy Die Without Completing Treatment.

Authors:  Shearwood McClelland; Namita Agrawal; Kevin Shiue; Gregory K Bartlett; Richard C Zellars; Gordon A Watson; Susannah G Ellsworth
Journal:  J Pain Symptom Manage       Date:  2019-04-25       Impact factor: 3.612

Review 3.  Epidemiology, Treatment, and Complications of Central Nervous System Metastases.

Authors:  Amy A Pruitt
Journal:  Continuum (Minneap Minn)       Date:  2017-12

4.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.

Authors:  B Borgelt; R Gelber; S Kramer; L W Brady; C H Chang; L W Davis; C A Perez; F R Hendrickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-01       Impact factor: 7.038

5.  Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.

Authors:  B Borgelt; R Gelber; M Larson; F Hendrickson; T Griffin; R Roth
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-12       Impact factor: 7.038

6.  Palliative radiation therapy in the management of brain metastases, spinal cord compression, and bone metastases.

Authors:  Samir V Sejpal; Amit Bhate; William Small
Journal:  Semin Intervent Radiol       Date:  2007-12       Impact factor: 1.513

7.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

Authors:  L Gaspar; C Scott; M Rotman; S Asbell; T Phillips; T Wasserman; W G McKenna; R Byhardt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

Review 8.  Whole-brain radiotherapy in the management of brain metastasis.

Authors:  Deepak Khuntia; Paul Brown; Jing Li; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

  8 in total
  2 in total

Review 1.  Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review.

Authors:  Adela Wu; Gabriela Ruiz Colón; Michael Lim
Journal:  Front Neurol       Date:  2022-02-17       Impact factor: 4.003

Review 2.  Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies.

Authors:  Margarita Martin; Raúl Hernanz; Carmen Vallejo; Leonardo Guerrero; Xabier Mielgo; Ana Lopez; Juan Carlos Trujillo-Reyes; Felipe Couñago
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.